Infermedica, a digital health company specialising in AI-powered symptom analysis and patient triage, has raised US$30m in new investment.
The capital will be used to support the further development of its Medical Guidance Platform (MGP) and adding new modules to cover the full primary care journey.
MGP leverages the same technology behind its Symptom Checker tool, which has been used by over 10 million users globally, to triage patients to the right level of care.
Infermedica plans to further develop the solution to enable handover to providers as part of the intake process, as well as automating follow-ups.
Infermedica also aims to increase its global commercial presence and expand its international team of industry and medical experts.
Founded in 2012 in Poland by CEO Piotr Orzechowski, Infermedica’s team grew by 80 per cent in 2021 to 180 specialists – including physicians, data scientists, and engineers, and 2022 will see Infermedica on the trajectory to double their workforce yet again.
Piotr said: “To date, we’ve spent over 60,000 hours of physicians’ work building one of the world’s most advanced medical knowledge bases of diseases, symptoms, and risk factors. We will deploy the new funds to execute our vision of making primary care more efficient and affordable by creating constantly improving AI technology for everyone on the planet.”
The series B funding round was led by One Peak, and supported by previous investors Karma Ventures, European Bank for Reconstruction and Development, Heal Capital, and Inovo Venture Partners.
Humbert de Liedekerke, managing partner, One Peak, said: “We are incredibly excited to back the Infermedica team as we share their vision of making healthcare more accessible and affordable by automating primary care.
“We have been particularly impressed with Infermedica’s clinical safety and accuracy, best-in-class user experience, ease of deployment, and customer service.
“We believe the company has all the ingredients in place to become the global standard for using AI to support patients and healthcare providers in all steps of the primary care journey and we look forward to supporting Infermedica in its next phase of explosive growth.”
The new investment – which follows a Series A funding round just over a year ago – brings the company’s total funding to US$44m.
By 2030, up to 5 billion people will be unable to access even basic healthcare, mainly due to provider shortages and burnout, says Infermedica.
Its stated mission is to ease the strain on global healthcare systems and make healthcare accessible, convenient and affordable by automating primary care.
